Targeting Mitochondrial Dysfunction

For our lead product, Imeglimin, preparations are underway for a New Drug Application in Japan. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting

Shareholders approved all proposed resolutions   LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for…

Read this Press Release: Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting

Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH

The study met its key objectives; PXL770 was observed to demonstrate a consistent PK profile in the likely-NASH patient population and was observed to be safe and well-tolerated Results demonstrate target…

Read this Press Release: Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH

Poxel Announces Participation in Upcoming Virtual Investor Conferences

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Participation in Upcoming Virtual Investor Conferences
Click here to show the previous slide Click here to show the next slide

Upcoming Events

European Association for the Study of the Liver 2020 International Liver Congress

Click here to show the previous slide Click here to show the next slide